Antibody

1,020개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,020 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastalePeking Union Medical CollegePreclinical

Surgery combined with secukinumab (Surgery combined with secukinumab)

Hidradenitis Suppurativa (HS); Hidradenitis Suppurativa (Acne Inversa) · Hidradenitis Suppurativa (HS)

#HidradenitisSuppurativaHS#Antibody#Preclinical#monoclonal-antibody#HidradenitisSuppurativaAcneInver+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBeijing Chest HospitalPhase 2

Surufatinib Durvalizumab EP/EC (Surufatinib Durvalizumab EP/EC)

Extensive-stage Small-cell Lung Cancer · Extensive-stage Small-cell Lung Cancer

#Extensive-stageSmall-cellLungCan#Antibody#Phase2#monoclonal-antibody#Beijing
Trials 1Status Active
AntibodyLimited DatastaleSanofiPreclinical

Systemic dupilumab (Systemic dupilumab)

Dermatitis, Atopic · Dermatitis, Atopic

#DermatitisAtopic#Antibody#Preclinical#monoclonal-antibody#Dermatitis+2
Trials 1Status Active
AntibodyLimited DatastaleUMC UtrechtPhase 2

FTD-TPI and bevacizumab (Systemic treatment, Systemic treatment (FTD-TPI and bevacizumab))

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#monoclonal-antibody#UMC
Trials 1Status Recruiting
AntibodyLimited DatastaleAgendiaApproved

trastuzumab (Herceptin, T + trastuzumab followed by CEF + trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Approved#monoclonal-antibody#Agendia
Trials 1Status Active
AntibodyLimited DatastaleTriumvira Immunologics, Inc.Phase 2

pembrolizumab (Keytruda, TAC01-HER2 plus pembrolizumab)

HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HER2PositiveGastricCancer+2
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 1

TACE combined with sintilimab and bevacizumab (TACE combined with sintilimab and bevacizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleSecond Affiliated Hospital of G…Phase 2

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase2#monoclonal-antibody#Second
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

atezolizumab (Tecentriq, TACE-HACI, plus atezolizumab-bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Sun
Trials 1Status Recruiting
AntibodyLimited DatastalePresage BiosciencesPhase 1

TAK-981 + Avelumab (TAK-981 + Avelumab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Active
AntibodyLimited DatastalePresage BiosciencesPhase 1

TAK-981 + Cetuximab (TAK-981 + Cetuximab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

TAS-102+bevacizumab+local treatment (TAS-102+bevacizumab+local treatment)

Metastatic Colorectal Cancer (CRC) · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleAsan Medical CenterApproved

TDM-based infliximab intravenous therapy (TDM-based infliximab intravenous therapy)

Crohn Disease; Infliximab · Crohn Disease

#CrohnDisease#Antibody#Approved#monoclonal-antibody#Infliximab+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

nivolumab (Opdivo, TJ033721, TJ033721 (givastomig) , nivolumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#AdvancedCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleI-Mab Biopharma US LimitedPhase 1

durvalumab (Imfinzi, TJ033721, TJ033721 (givastomig), durvalumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#AdvancedCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 2

pembrolizumab (Keytruda, TJ107 +Pembrolizumab)

Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#Antibody#Phase2#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleAbbVieApproved

infliximab, adalimumab, etanercept (TNF blockers, TNF blockers (infliximab, adalimumab, etanercept))

Arthritis, Rheumatoid; Spondylitis, Ankylosing · Arthritis, Rheumatoid

#ArthritisRheumatoid#Antibody#Approved#monoclonal-antibody#Arthritis+3
Trials 1Status Active
AntibodyLimited DatastaleUniversity of CalgaryApproved

adalimumab (Humira, TNFa Antagonist - Adalimumab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#monoclonal-antibody#University
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity of CalgaryApproved

TNFa Antagonist - Infliximab (TNFa Antagonist - Infliximab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#monoclonal-antibody#University
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

JS001 (TORIPALIMAB INJECTION, TORIPALIMAB INJECTION(JS001 ))

Biliary Tract Cancer (BTC) · Biliary Tract Cancer (BTC)

#BiliaryTractCancerBTC#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting

42 / 51 pages

← PreviousNext →